GHRP-1: Mechanism, Dosing & Research Data

GHRP-1 was the first synthetic growth hormone-releasing peptide developed, created by Cyril Bowers in 1977 as a shorter, more stable analog of enkephalin/" class="wiki-internal-link">met-enkephalin with unexpected GH-releasing properties. While since superseded by GHRP-2 and GHRP-6 in research and clinical use, GHRP-1 established the ghrelin/" class="wiki-internal-link">ghrelin/GHS-R1a pharmacological pathway and remains historically significant as the progenitor of all synthetic GH secretagogues.

Mechanism of Action

Binds GHS-R1a at pituitary somatotrophs and hypothalamic neurons, triggering Gq/11/PLC/IP3 and cAMP pathways that amplify pulsatile GH release
Synergizes with endogenous GHRH via complementary receptor pathways; the synergy between a GHRP and GHRH defines modern GH secretagogue protocols
Weaker GH release potency than GHRP-2 and hexarelin at equimolar doses; established mechanism but not the preferred agent
Does not meaningfully elevate prolactin or cortisol at therapeutic doses, distinguishing it from hexarelin at higher doses
Appetite stimulation via GHS-R1a in hypothalamus (same as all GHRPs); less pronounced than GHRP-6 due to lower binding affinity

Research Findings

Bowers (1980): GHRP-1 identified as a potent, non-somatostatin-inhibited GH releaser; established the concept of synthetic GH secretagogues independent of GHRH
GHRP-1 IV infusion in healthy men produced peak GH of 20-40 ng/mL at 50-100 mcg IV; comparable but slightly lower than GHRP-2 at same dose
GHRP-1 combined with GHRH 1-29 showed synergistic GH release (3-5x greater than either alone); established the combinatorial protocol standard
Used as reference compound in GHS-R1a pharmacological characterization; Ki ~5-15 nM at human GHS-R1a
Historical interest: GHRP-1 led directly to the discovery of endogenous ghrelin (2000) as the natural GHS-R1a ligand

Research Protocols

Historical research dose: 1-2 mcg/kg IV or 100-200 mcg SC in GH stimulation studies; peak GH at 15-30 minutes
GHS-R1a binding: Ki ~5-15 nM; used as reference in receptor characterization alongside GHRP-2 and ghrelin
Combinatorial: GHRP-1 (100 mcg) + GHRH (1 mcg/kg) SC; measure serum GH at 30 and 60 minutes
Not used clinically; superseded by GHRP-2, GHRP-6, hexarelin, and ipamorelin in research and practice

Interactions

GHRH (sermorelin/CJC-1295): synergistic GH release; defined the GHRP + GHRH combinatorial paradigm
Somatostatin: GHRP-1 partially overrides somatostatin-mediated GH suppression (key early finding establishing GHRPs as somatostatin-independent)
GHRP-2, GHRP-6, hexarelin, ipamorelin: all bind same GHS-R1a receptor; GHRP-1 has slightly lower potency than these successors

Safety Profile

Research peptide only. Not clinically approved. Short-term use in research studies well tolerated. Safety profile expected similar to GHRP-2/GHRP-6 (water retention, mild cortisol rise, increased hunger). Primarily of historical and pharmacological interest.